Biosenic SA

Bone Therapeutics signs definitive subscription agreement for a maximum of EUR 5M convertible bonds facility with ABO

31 May 2022 00:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics enters into exclusive reverse merger discussions with Medsenic

12 May 2022 00:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics to host Annual General Meeting and Extraordinary General Meeting on 8 June 2022

09 May 2022 00:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics announces 2021 full year results

29 Apr 2022 00:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics Secures EUR 5 Million Financing

12 Apr 2022 00:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics to strategically focus on lead cell therapy product ALLOB

29 Mar 2022 00:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics SA: Transparency notification received from Nyenburgh Holding NV

23 Mar 2022 01:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics provides fourth quarter 2021 business update and 2022 outlook

19 Jan 2022 00:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics SA: Transparency notification received from S.R.I.W. SA and Sofipôle SA

23 Dec 2021 00:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics SA: Transparency notification received from Nyenburgh Holding NV

10 Dec 2021 00:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics SA: Information on the total number of voting rights and shares

09 Dec 2021 00:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics announces closing of private placement

08 Dec 2021 00:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics Successfully Raises EUR 3.3 Million in Private Placement

03 Dec 2021 00:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics and Link Health sign a non-binding term sheet for the global rights of ALLOB

29 Nov 2021 00:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics Provides Third Quarter 2021 Business Update

26 Oct 2021 00:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics appoints Scientific Advisory Board for iMSC cell and gene therapy platform development

12 Oct 2021 00:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics signs research partnership with Implant Therapeutics to access induced Pluripotent Stem Cells (iPSC)

28 Sep 2021 00:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics appoints Lieve Creten as interim Chief Financial Officer

21 Sep 2021 00:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics reports half year 2021 results

08 Sep 2021 00:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics SA reacts to the press release issued by Hybrigenics

07 Sep 2021 00:00:00 By Nasdaq GlobeNewswire